Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
CTMX, HSDT and SNSE are among premarket gainers
Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.